Illumina Inc (ILMN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Illumina Inc (ILMN) has a cash flow conversion efficiency ratio of 0.104x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($321.00 Million) by net assets ($3.08 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Illumina Inc market cap and net worth for the company's overall valuation and market capitalisation.
Illumina Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Illumina Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Illumina Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Illumina Inc ranked by their cash flow conversion efficiency. Explore Illumina Inc (ILMN) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dollar Tree Inc
NASDAQ:DLTR
|
0.328x |
|
Companhia de Saneamento Básico do Estado de São Paulo - SABESP
F:SAJA
|
0.021x |
|
Falabella
SN:FALABELLA
|
0.018x |
|
Sinopac Financial Holdings Co Ltd
TW:2890
|
0.289x |
|
MACOM Technology Solutions Holdings Inc
NASDAQ:MTSI
|
0.004x |
|
TECHTRONIC INDS ADR/5
F:TIB
|
N/A |
|
Powszechny Zaklad Ubezpieczen SA
WAR:PZU
|
0.129x |
|
Grace Fabric Technology Co Ltd
SHG:603256
|
0.028x |
Annual Cash Flow Conversion Efficiency for Illumina Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Illumina Inc from 1999 to 2025. View ILMN stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.08 Billion | $1.08 Billion | 0.350x | -0.78% |
| 2024-12-31 | $2.37 Billion | $837.00 Million | 0.353x | +323.93% |
| 2023-12-31 | $5.75 Billion | $478.00 Million | 0.083x | +40.07% |
| 2022-12-31 | $6.60 Billion | $392.00 Million | 0.059x | +17.06% |
| 2021-12-31 | $10.74 Billion | $545.00 Million | 0.051x | -77.94% |
| 2020-12-31 | $4.69 Billion | $1.08 Billion | 0.230x | +0.99% |
| 2019-12-31 | $4.61 Billion | $1.05 Billion | 0.228x | -22.07% |
| 2018-12-31 | $3.91 Billion | $1.14 Billion | 0.292x | -0.79% |
| 2017-12-31 | $2.97 Billion | $875.00 Million | 0.295x | -0.76% |
| 2016-12-31 | $2.31 Billion | $687.24 Million | 0.297x | -15.31% |
| 2015-12-31 | $1.88 Billion | $659.60 Million | 0.351x | +2.17% |
| 2014-12-31 | $1.46 Billion | $501.27 Million | 0.343x | +36.17% |
| 2013-12-31 | $1.53 Billion | $386.42 Million | 0.252x | +13.86% |
| 2012-12-31 | $1.32 Billion | $291.87 Million | 0.221x | -33.54% |
| 2011-12-31 | $1.08 Billion | $358.14 Million | 0.333x | +46.36% |
| 2010-12-31 | $1.20 Billion | $272.57 Million | 0.228x | +12.72% |
| 2009-12-31 | $864.25 Million | $174.50 Million | 0.202x | +94.96% |
| 2008-12-31 | $848.60 Million | $87.88 Million | 0.104x | -24.27% |
| 2007-12-31 | $411.68 Million | $56.29 Million | 0.137x | -13.28% |
| 2006-12-31 | $247.34 Million | $39.00 Million | 0.158x | +226.90% |
| 2005-12-31 | $72.50 Million | $-9.01 Million | -0.124x | +54.13% |
| 2004-12-31 | $72.26 Million | $-19.57 Million | -0.271x | +29.69% |
| 2003-12-31 | $47.39 Million | $-18.26 Million | -0.385x | -7.99% |
| 2002-12-31 | $71.74 Million | $-25.59 Million | -0.357x | -248.70% |
| 2001-12-31 | $106.79 Million | $-10.93 Million | -0.102x | +11.29% |
| 2000-12-31 | $124.10 Million | $-14.31 Million | -0.115x | -27.07% |
| 1999-12-31 | $32.03 Million | $-2.91 Million | -0.091x | -- |
About Illumina Inc
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and … Read more